China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

Core Viewpoint - China Pharma Holdings Inc. plans to implement a 1-for-10 reverse stock split effective April 15, 2025, with trading to begin on a split-adjusted basis on that day [1]. Group 1: Reverse Stock Split Details - The reverse stock split was authorized by the Company's Board of Directors on October 22, 2024, and adopted by stockholders during the Annual Meeting on December 22, 2024 [2]. - The fixed ratio of 1:10 for the reverse stock split was determined on March 26, 2025 [2]. - Upon the effectiveness of the reverse stock split, every 10 shares will convert into one share, with no fractional shares issued; any resulting fractional shares will be rounded up to the next whole number [3]. Group 2: Company Overview - China Pharma Holdings, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing products for high-incidence and high-mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases [4]. - The Company operates a cost-effective business model driven by market demand and has a nationwide distribution network across major cities and provinces in China [4]. - The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province [4].